A promising strategy to reduce the impact of viral infectious diseases, such as influenza, is the use of attenuated, live viruses as vaccines.
However, the usefulness of traditional live-attenuated virus vaccines has often been limited by suboptimal immunogenicity, safety concerns, or cumbersome manufacturing processes and techniques. In addition, immune escape due to rapid viral evolution poses a further challenge for traditional influenza vaccines.
Recently, a research team has proposed a new live-attenuated influenza vaccine approach — generating proteolysis-targeting chimeric (PROTAC) influenza A virus as a live-attenuated vaccine by utilizing the endogenous ubiquitin-proteasome system of host cells to degrade viral proteins. The results were published in Nature Biotechnology.
Given that virus replication depends on virally encoded proteins, manipulation of viral protein stability by utilizing the protein degradation machinery of the host cell may represent a potential approach to switch the viral life cycle on and off for vaccine development. Thus, the researchers designed proteolysis-targeting chimeric (PROTAC) viruses by fusing a conditionally removable proteasome-targeting domain (PTD) to influenza viral proteins.
The PTD was designed to contain a proteasome-targeting peptide and a tobacco etch virus cleavage site (TEVcs) linker. It was used to selectively induce proteasomal degradation of viral proteins of interest; however, the TEVcs linker could be selectively cleaved by the tobacco etch virus protease (TEVp) to separate the viral proteins from the PTD, thus sparing them from degradation.
Accordingly, the researchers engineered the genome of influenza A viruses in TEVp-expressing stable cell lines engineered for virus production to introduce the conditionally removable PTD, generating fully infective PROTAC viruses that were live-attenuated by the host protein degradation machinery upon infection.
In mouse and ferret models, PROTAC viruses were sufficiently attenuated but able to elicit robust and broad humoral, mucosal, and cellular immunity. As a result, they provided broad protection against homologous and heterologous virus challenges.
"This PROTAC vaccine technology could also be useful for generating live-attenuated vaccines against other types of pathogens," said the senior author.
https://www.nature.com/articles/s41587-022-01381-4
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fgeneration-of-a-live&filter=22
A new live-attenuated influenza A vaccine
- 1,334 views
- Added
Latest News
Hyperactivation of memory c…
By newseditor
Posted 30 May
Maternal obesity may promot…
By newseditor
Posted 30 May
The neuronal basis of opioi…
By newseditor
Posted 30 May
Circadian clock can be leve…
By newseditor
Posted 30 May
Connecting genetic risk for…
By newseditor
Posted 30 May
Other Top Stories
Largest study ever confirms psychological sex differences and autis…
Read more
Defective DNA damage repair and genome chaos may lead to brain tumor
Read more
Is pain a self-fulfilling prophecy
Read more
Better heart health from metabolism of dietary fiber by beneficial…
Read more
How your muscles form
Read more
Protocols
Accessible high-speed image…
By newseditor
Posted 30 May
SEMORE: SEgmentation and MO…
By newseditor
Posted 26 May
Spatially resolved lipidomi…
By newseditor
Posted 24 May
Efficient expansion and CRI…
By newseditor
Posted 21 May
Massively parallel in vivo…
By newseditor
Posted 20 May
Publications
Phase locking of hippocampa…
By newseditor
Posted 30 May
Interactions between physic…
By newseditor
Posted 30 May
Lipid-associated macrophage…
By newseditor
Posted 30 May
Maternal obesity increases…
By newseditor
Posted 30 May
Why cells need iron: a comp…
By newseditor
Posted 30 May
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar